SP
Sat Paul Jassal
About Sat Paul Jassal
Data last updated:
Sat Paul Jassal is a Director at Evertogen Life Sciences Limited (since 2021) and Director at Organosyn Life Sciences Private Limited (since 2016). The companies operate in Pharma. The 2 current companies with reported revenue have a combined latest revenue of ₹130 Cr; the largest is Evertogen Life Sciences Limited at ₹89.28 Cr (FY 2024).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 18 Jun 2021 | 2013 | ₹89.28 Cr (FY 2024) | Active | |
| Director | 08 Jun 2016 | 2011 | ₹40.64 Cr (FY 2025) | Active |
Board colleagues of Sat Paul Jassal
| Name | DIN | Company | Designation |
|---|---|---|---|
| Akhila Thotapally | Evertogen Life Sciences Limited | Company Secretary | |
| Manav Jassal | 03059931 | Evertogen Life Sciences Limited , Organosyn Life Sciences Private Limited | Director |
| Sherifuddin Sheriff Shaik | 02201440 | Evertogen Life Sciences Limited | Director |
| Subbarao Kattamuri | 00107121 | Evertogen Life Sciences Limited | Managing Director |
| Sushma Kattamuri | 02986836 | Evertogen Life Sciences Limited | Director |
| Vikram Ravindra Mamidipudi | 00008241 | Evertogen Life Sciences Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Sat Paul Jassal
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sat Paul Jassal
Sat Paul Jassal currently holds 2 directorships: Evertogen Life Sciences Limited (Director, since 18 Jun 2021, revenue ₹89.28 Cr (FY 2024)); Organosyn Life Sciences Private Limited (Director, since 08 Jun 2016, revenue ₹40.64 Cr (FY 2025)).
Sat Paul Jassal was first appointed on 08 Jun 2016 as Director at Organosyn Life Sciences Private Limited. The most recent appointment on record is 18 Jun 2021 at Evertogen Life Sciences Limited.
The 2 current companies of Sat Paul Jassal that report revenue have a combined latest revenue of ₹130 Cr: Evertogen Life Sciences Limited ₹89.28 Cr (FY 2024); Organosyn Life Sciences Private Limited ₹40.64 Cr (FY 2025).
The current boards of Sat Paul Jassal's companies include Akhila Thotapally (Evertogen Life Sciences Limited), Manav Jassal (Evertogen Life Sciences Limited), Sherifuddin Sheriff Shaik (Evertogen Life Sciences Limited), Subbarao Kattamuri (Evertogen Life Sciences Limited), Sushma Kattamuri (Evertogen Life Sciences Limited), Vikram Ravindra Mamidipudi (Evertogen Life Sciences Limited).